Amyloid-β, tau, and dementia

Journal of Alzheimer's Disease

Volumn 17, Issue 4, 2009, Pages 729-736

  Takashima, Akihiko ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

Amyloid ; Dementia; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; AXOPLASM FLOW; COGNITIVE DEFECT; CYTOTOXICITY; DISEASE COURSE; ENTORHINAL CORTEX; FRONTOTEMPORAL DEMENTIA; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; ANIMAL; BRAIN; MEMORY DISORDER; METABOLISM; PATHOLOGY; PSYCHOLOGY;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; DISEASE PROGRESSION; ENTORHINAL CORTEX; HUMANS; MEMORY DISORDERS; NEUROFIBRILLARY TANGLES; TAU PROTEINS;

EID: 68949150683     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1090     Document Type: Review

References (57)

1. Reisberg B, Ferris SH, de Leon MJ, Crook T (1982) The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 139, 1136-1139.
2. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12, 383-388.
3. Hutton M, Perez-Tur J, Hardy J (1998) Genetics of Alzheimer's disease. Essays Biochem 33, 117-131.
4. Hardy J (2006) Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis 9 (3 Suppl), 151-153.
5. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
6. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
7. Yankner BA, Duffy LK, Kirschner DA (1990) Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250, 279-282.
8. Busciglio J, Lorenzo A, Yeh J, Yankner BA (1995) beta-amyloid fibrils induce tau phosphorylation and loss of micro-tubule binding. Neuron 14, 879-888.
9. Lorenzo A, Yankner BA (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A 91, 12243-12247.
10. Ashe KH (2001) Learning and memory in transgenic mice modeling Alzheimer's disease. Learn Mem 8, 301-308.
11. Morgan D (2003) Learning and memory deficits in APP trans-genic mouse models of amyloid deposition. Neurochem Res 28, 1029-1034.
12. Delacourte A (2006) From physiopathology to treatment of Alzheimer's disease. Rev Neurol (Paris) 162, 909-912.
13. Yankner BA (1992) Commentary and perspective on studies of beta amyloid neurotoxicity. Neurobiol Aging 13, 615-616.
14. Lorenzo A, Razzaboni B, Weir GC, Yankner BA (1994) Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368, 756-760.
15. Cribbs DH, Pike CJ, Weinstein SL, Velazquez P, Cotman CW (1997) All-D-enantiomers of beta-amyloid exhibit similar biological properties to all-L-beta-amyloids. J Biol Chem 272, 7431-7436.
16. Yoshiike Y, Akagi T, Takashima A (2007) Surface structure of amyloid-beta fibrils contributes to cytotoxicity. Biochemistry 46, 9805-9812.
17. Glabe CG (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27, 570-575.
18. Look GC, Jerecic J, Cherbavaz DB, Pray TR, Breach JC, Crosier WJ, Igoudin L, Hironaka CM, Lowe RM, McEntee M, Ruslim-Litrus L, Wu HM, Zhang S, Catalano SM, Goure WF, Summa D, Krafft GA (2007) Discovery of ADDL - targeting small molecule drugs for Alzheimer's disease. Curr Alzheimer Res 4, 562-567.
19. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ (2002) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30, 552-557.
20. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-D- aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282, 11590-11601.
21. Klein WL (2002) Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41, 345-352.
22. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trom-mer BL (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924, 133-140.
23. Knobloch M, Farinelli M, Konietzko U, Nitsch RM, Mansuy IM (2007) Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci 27, 7648-7653.
24. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocam-pal long-term potentiation in vivo. Nature 416, 535-539.
25. Chapman PF (2000) Alzheimer's disease: model behaviour. Nature 408, 915-916.
26. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5, 452-457.
27. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11, 556-561.
28. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME, Janus C, Chishti MA, Horne P, Westaway D, Fraser PE, Mount HT, Przybylski M, St George-Hyslop P (2002) Ther-apeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8, 1263-1269.
29. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985.
30. Younkin SG (2001) Amyloid beta vaccination: reduced plaques and improved cognition. Nat Med 7, 18-19.
31. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216-223.
32. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754.
33. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Pe-tersen RC, Parisi JE, Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41, 17-24.
34. Spillantini MG, Goedert M (1998) Tau protein pathology in neurodegenerative diseases. Trends Neurosci 21, 428-433.
35. Hutton M (2001) Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms. Neurology 56 (11 Suppl 4), 21-25.
36. Hutton M (2000) Molecular genetics of chromosome 17 tauopathies. Ann N Y Acad Sci 920, 63-73.
37. Ingram EM, Spillantini MG (2002) Tau gene mutations: dissecting the pathogenesis of FTDP-17. Trends Mol Med 8, 555-562.
38. GoedertM,SpillantiniMG(2000) Tau mutationsin frontotem-poral dementia FTDP-17 and their relevance for Alzheimer's disease. Biochim Biophys Acta 1502, 110-121.
39. van Swieten JC, Rosso SM, van Herpen E, Kamphorst W, Ravid R, Heutink P (2004) Phenotypic variation in frontotem-poral dementia and parkinsonism linked to chromosome 17. Dement Geriatr Cogn Disord 17, 261-264.
40. Braak H, Braak E (1996) Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 165, 3-12.
41. Samuel W, Masliah E, Hill LR, Butters N, Terry R (1994) Hip-pocampal connectivity and Alzheimer's dementia: effects of synapse loss and tangle frequency in a two-component model. Neurology 44, 2081-2088.
42. Callahan LM, Selski DJ, Martzen MR, Cheetham JE, Coleman PD (1994) Preliminary evidence: decreased GAP-43 message in tangle-bearing neurons relative to adjacent tangle-free neurons in Alzheimer's disease parahippocampal gyrus. Neurobi-ol Aging 15, 381-386.
43. Sato-Harada R, Okabe S, Umeyama T, Kanai Y, Hirokawa N (1996) Microtubule-associated proteins regulate microtubule function as the track for intracellular membrane organelle transports. Cell Struct Funct 21, 283-295.
44. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156, 1051-1063.
45. Thies E, Mandelkow EM (2007) Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci 27, 2896-2907.
46. Dixit R, Ross JL, Goldman YE Holzbaur EL (2008) Differential regulation of dynein and kinesin motor proteins by tau. Science 319, 1086-1089.
47. Morfini G, Pigino G, Mizuno N, Kikkawa M, Brady ST (2007) Tau binding to microtubules does not directly affect microtubule-based vesicle motility. J Neurosci Res 85, 2620-2630.
48. Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Tro-janowski JQ, Lee VM (1999) Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24, 751-762.
49. Yuan A, Kumar A, Peterhoff C, Duff K, Nixon RA (2008) Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J Neurosci 28, 1682-1687.
50. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingels-son M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481.
51. Spires-Jones TL, de Calignon A, Matsui T, Zehr C, Pitstick R, Wu HY, Osetek JD, Jones PB, Bacskai BJ, Feany MB, Carlson GA, Ashe KH, Lewis J, Hyman BT (2008) In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. J Neurosci 28, 862-867.
52. Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H, Miyasaka T, Murayama S, Ikai A, Takashima A (2007) Granular tau oligomers as intermediates of tau filaments. Biochemistry 46, 3856-3861.
53. Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima (2006) A Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res 54, 197-201.
54. Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F (2006) Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofib-rillary tangles do not revert. J Neurochem 99, 1445-1455.
55. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102, 6990-6995.
56. Wischik CM, Bentham P, Wischik DJ, Seng KM (2008) Tau aggregation inhibitor (TAI) therapy with REMBER™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimers Dement 4 (Suppl), T167.
57. Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, Takeda A, Nunomura A, Smith MA (2005) Tau phosphoryla-tion in Alzheimer's disease: pathogen or protector? Trends Mol Med 11, 164-169.